Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pembrolizumab with or without olaparib following pembrolizumab with chemoradiation therapy for previously untreated, advanced, stage III non-small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab with chemoradiotherapy for treating high-risk locally advanced cervical cancer Chemoradiotherapy , Pembrolizumab (Keytruda; MK-3475) Cervical cancer Female Reproductive Cancer 2022 View  |  Download
Pembrolizumab and chemoradiation for treating muscle-invasive, non-metastatic bladder cancer Chemoradiotherapy , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications